Vanguard National Trust’s BioNTech BNTX Stock Holding History

Vanguard National Trust’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.68K	Hold	61	–	–	﹤0.01%	652
2026 Q1	$5.42K	Buy	+61	New	+$6.27K	﹤0.01%	596

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard National Trust's BNTX Position: Q2 2026 in Review

Vanguard National Trust held its BioNTech (BNTX) position steady in Q2 2026 at 61 shares worth $5.68K. The position accounts for ﹤0.01% of the portfolio, ranked #652.

Vanguard National Trust first reported a position in BNTX in Q1 2026 and has held it in 2 quarters since. 279 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Vanguard National Trust held 61 shares of BioNTech worth $5.68K as of Q2 2026.
Vanguard National Trust left its BioNTech share count unchanged in Q2 2026.
BioNTech made up ﹤0.01% of Vanguard National Trust's portfolio in Q2 2026, its #652 holding.
Vanguard National Trust first reported a position in BioNTech in Q1 2026 and has held it in 2 quarters since.
279 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.